Ceralasertib-Mediated ATR Inhibition Combined With Olaparib in Advanced Cancers Harboring DNA Damage Response and Repair Alterations (Olaparib Combinations)

Poly (ADP-ribose) polymerase (PARP) inhibitors have emerged as promising therapy in cancers with homologous recombination repair deficiency. However, efficacy is limited by both intrinsic and acquired resistance. The Olaparib Combinations basket trial explored olaparib alone and in combination with...

Descripción completa

Detalles Bibliográficos
Autores principales: Mahdi, Haider, Hafez, Navid, Doroshow, Deborah, Sohal, Davendra, Keedy, Vickie, Do, Khanh T., LoRusso, Patricia, Jürgensmeier, Juliane, Avedissian, Manuel, Sklar, Jeffrey, Glover, Colin, Felicetti, Brunella, Dean, Emma, Mortimer, Peter, Shapiro, Geoffrey I., Eder, Joseph Paul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2021
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437220/
https://www.ncbi.nlm.nih.gov/pubmed/34527850
http://dx.doi.org/10.1200/PO.20.00439

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8437220/
https://www.ncbi.nlm.nih.gov/pubmed/34527850
http://dx.doi.org/10.1200/PO.20.00439

Ejemplares similares